Clinical Trial Update: mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates the combination of a modified FOLFIRI regimen with Nimotuzumab as second-line therapy for esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• mFOLFIRI

Snippet

Sponsor: Peking University | Conditions: Advanced Esophageal Carcinoma | Phase 2 | Status: UNKNOWN